Skip to content
10-Q

Quarterly Report

Vir Biotechnology, Inc. VIR

0001628280-25-023291

← back to feed
Filed
May 8, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Apr 30, 2025 138.24M sh
Current Liabilities Q1 2025 · Mar 31, 2025 $137.29M
Current Liabilities Q1 2025 · Dec 31, 2024 $119.66M
Total Liabilities Q1 2025 · Mar 31, 2025 $263.91M
Total Liabilities Q1 2025 · Dec 31, 2024 $248.43M
Current Assets Q1 2025 · Mar 31, 2025 $932.21M
Current Assets Q1 2025 · Dec 31, 2024 $1.04B
Total Assets Q1 2025 · Mar 31, 2025 $1.31B
Total Assets Q1 2025 · Dec 31, 2024 $1.4B
Cost Of Revenue Q1 2025 · Mar 31, 2025 $0
Cost Of Revenue Q1 2025 · Mar 31, 2024 $59K
Revenue Q1 2025 · Mar 31, 2025 $3.03M
Revenue Q1 2025 · Mar 31, 2024 $56.38M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $222.95M
Cash And Equivalents Q1 2025 · Mar 31, 2024 $160.71M
Shares Diluted Q1 2025 · Mar 31, 2024 135.28M sh
Capex Q1 2025 · Mar 31, 2024 $1.87M
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$109.39M
Stockholders Equity Q1 2025 · Mar 31, 2024 $1.55B
Stockholders Equity Q1 2025 · Dec 31, 2023 $1.59B
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.48
Eps Basic Q1 2025 · Mar 31, 2024 −$0.48
Sga Expense restated Q1 2025 · Mar 31, 2024 $36.32M
Rd Expense Q1 2025 · Mar 31, 2024 $100.13M
Net Income Q1 2025 · Mar 31, 2024 −$65.28M
Operating Income Q1 2025 · Mar 31, 2024 −$80.08M